We have not reviewed the charts of United Therapeutics Corporation (UTHR) since Dec. 8, 2017 and then we had a long-term Point and Figure target of $175. Prices finally reached that long-term price target this year.
Why have we circled back to UTHR? We have been finding more and more bullish biotech charts since our review of the exchange-traded funds SPDR S&P Biotech ( XBI) and iShares Nasdaq Biotechnology ( IBB) on April 14. Money continues to flow into these names. 
In this updated daily bar chart of UTHR, below, we can see that prices have been in a strong uptrend since October. Prices are trading above the rising 50-day moving average line and the rising 200-day moving average line.
The On-Balance-Volume (OBV) line shows a positive trend the past twelve months telling us that buyers of UTHR have been more aggressive. The Moving Average Convergence Divergence (MACD) oscillator is above the zero-line, but has narrowed in recent days. The oscillator may or may not cross to the downside -- my bet is for further gains.
In this weekly bar chart of UTHR, below, we went back ten years to show you the "big picture." This year prices broke a downtrend from the 2015 highs. In addition to breaking the downtrend, UTHR has also broken above the 2015 zenith. Prices are trading above the rising 40-week moving average line. The weekly OBV line is on an uptrend from 2019. The MACD oscillator is very bullish.
In this daily Point and Figure chart of UTHR, below, we can see that the shares have reached and exceeded their price target in the $202 area.
In this weekly Point and Figure chart of UTHR, below, we can see a price target of $312.
Bottom line strategy: UTHR and many other companies in this space are showing good strength. Aggressive traders could go long UTHR at current levels and on any shallow dip. Risk below $190. The $312 area is our price objective.
